ReviewActa diabetologica2011
Gut microbiota and diabetes: from pathogenesis to therapeutic perspective.
Review in Acta diabetologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03552991 (Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus), which is not on this map. Cited by 99 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus
Who cites it
99 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- A meta-analysis of the therapeutic effect of probiotic intervention in obese or overweight adolescents.Frontiers in endocrinology · 2024Pooled it
- The effects of probiotic administration on patients with prediabetes: a meta-analysis and systematic review.Journal of translational medicine · 2022Pooled it
- Probiotics have beneficial metabolic effects in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials.Scientific reports · 2020Pooled it
- Effect of Probiotics on Glucose and Lipid Metabolism in Type 2 Diabetes Mellitus: A Meta-Analysis of 12 Randomized Controlled Trials.Medical science monitor : international medical journal of experimental and clinical research · 2017Pooled it
- Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial.European journal of nutrition · 2017Trial
- Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial.Journal of health, population, and nutrition · 2015Trial
- Effects ofGut microbes · 2026Article
- Effects of Replacing Soybean Meal with Different Proportions of Black Soldier Fly Larvae Meal on Antioxidant Indicators, Immune System, and Gut Health of Xichuan Black-Bone Chickens.Antioxidants (Basel, Switzerland) · 2026Article
- Investigating the Risk Factors Associated with Type 1 Diabetes (T1D) in the South of Iran: A Casecontrol Study.Current diabetes reviews · 2026Article
- The Gut Nexus: Unraveling Microbiota-Mediated Links Between Type 2 Diabetes and Colorectal Cancer.Nutrients · 2025Review
- Preharvest Control ofMicroorganisms · 2025Review
- The Comparison of the Gut Microbiome Composition, Serum Inflammatory Markers and Faecal Short-Chain Fatty Acids Among Individuals With Type 1 and 2 Diabetes Mellitus With Healthy Controls: A Case-Control Study.Endocrinology, diabetes & metabolism · 2025Article
- Unveiling the interplay among skin microbiota, cytokines, and T2DM: an insightful Mendelian randomization study.Nutrition & metabolism · 2025Article
- Neuroendocrine control of glucose homeostasis: integrative mechanisms from the hypothalamus to the brainstem.Frontiers in endocrinology · 2025Review
- The therapeutic effects of dendrobium officinale polysaccharides on diabetes mellitus: from the perspective of gut microbiota.Frontiers in endocrinology · 2025Review
- Correlation of Differentially Expressed lncRNAs with Intestinal Flora Imbalance, Small Intestinal Permeability, and Glucose Uptake in T2DM Mice.Applied biochemistry and biotechnology · 2024Article
- Gut and oral microbiota in gynecological cancers: interaction, mechanism, and therapeutic value.NPJ biofilms and microbiomes · 2024Review
- Association of Circulating Markers of Microbial Translocation and Hepatic Inflammation with Liver Injury in Patients with Type 2 Diabetes.Biomedicines · 2024Article
- The Role ofJournal of clinical medicine · 2024Review
- Oral-gut microbial transmission promotes diabetic coronary heart disease.Cardiovascular diabetology · 2024Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than several hundreds of millions of people will be diabetic and obese over the next decades in front of which the actual therapeutic approaches aim at treating the consequences rather than causes of the impaired metabolism. This strategy is not efficient and new paradigms should be found. The wide analysis of the genome cannot predict or explain more than 10-20% of the disease, whereas changes in feeding and social behavior have certainly a major impact. However, the molecular mechanisms linking environmental factors and genetic susceptibility were so far not envisioned until the recent discovery of a hidden source of genomic diversity, i.e., the metagenome. More than 3 million genes from several hundreds of species constitute our intestinal microbiome. First key experiments have demonstrated that this biome can by itself transfer metabolic disease. The mechanisms are unknown but could be involved in the modulation of energy harvesting capacity by the host as well as the low-grade inflammation and the corresponding immune response on adipose tissue plasticity, hepatic steatosis, insulin resistance and even the secondary cardiovascular events. Secreted bacterial factors reach the circulating blood, and even full bacteria from intestinal microbiota can reach tissues where inflammation is triggered. The last 5 years have demonstrated that intestinal microbiota, at its molecular level, is a causal factor early in the development of the diseases. Nonetheless, much more need to be uncovered in order to identify first, new predictive biomarkers so that preventive strategies based on pre- and probiotics, and second, new therapeutic strategies against the cause rather than the consequence of hyperglycemia and body weight gain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.